Nasdaq · CIK 0001711754
INMB Inmune Bio, Inc.
Insider trading from SEC Form 4. Last filing 20 d ago.
In brief
Inmune Bio, Inc. (INMB) has 26 SEC Form 4 filings on file from 9 insiders, the latest filed on Sep 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Inmune Bio, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The newest 50 of 120 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Ronnie Duane Clark director | AGrant or award Stock Optionsderivative | +100,000 | $0.00 | $0 | 100,000 | 20 d ago |
| Sep 15, 2026 | James Sapirstein director | AGrant or award Stock Optionsderivative | +100,000 | $0.00 | $0 | 100,000 | 26 d ago |
| Jul 2, 2026 | David J Moss Chief Executive Officer | MOption exercise Common Stock | +9,014 | $1.40 | $13k | 1,294,883 | Jul 7, 2026 |
| Jul 2, 2026 | Mark William Lowdell Chief Scientific Officer | MOption exercise Common Stock | +7,211 | $1.40 | $10k | 1,518,017 | Jul 7, 2026 |
| Jul 2, 2026 | Scott Juda director | MOption exercise Common Stock | +14,801 | $1.40 | $21k | 86,404 | Jul 7, 2026 |
| Jul 2, 2026 | David J Moss Chief Executive Officer | XIn-the-money exercise Common Stock Purchase Warrantderivative | -9,014 | $0.13 | $1,127 | 9,014 | Jul 7, 2026 |
| Jul 2, 2026 | Mark William Lowdell Chief Scientific Officer | XIn-the-money exercise Common Stock Purchase Warrantderivative | -7,211 | $0.13 | $901 | 7,212 | Jul 7, 2026 |
| Jul 2, 2026 | Scott Juda director | XIn-the-money exercise Common Stock Purchase Warrantderivative | -14,801 | $0.13 | $1,850 | 14,802 | Jul 7, 2026 |
| Dec 1, 2025 | Scott Juda director | AGrant or award Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 2, 2025 |
| Dec 1, 2025 | Cory Randall Ellspermann CFO | AGrant or award Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 2, 2025 |
| Dec 1, 2025 | Marcia Allen director | AGrant or award Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 2, 2025 |
| Dec 1, 2025 | James Kelly Ganjei director | AGrant or award Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 2, 2025 |
| Dec 1, 2025 | Timothy j Schroeder director | AGrant or award Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 2, 2025 |
| Dec 1, 2025 | Mark William Lowdell Chief Scientific Officer | AGrant or award Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Dec 2, 2025 |
| Dec 1, 2025 | David J Moss Chief Executive Officer | AGrant or award Option (right to buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Dec 2, 2025 |
| Nov 18, 2025 | Marcia Allen director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | James Kelly Ganjei director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Timothy j Schroeder director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Mark William Lowdell Chief Scientific Officer | DDisposition to issuer Stock Option (right to buy)derivative | -400,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | David J Moss Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -400,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Scott Juda director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Cory Randall Ellspermann Interim CFO | DDisposition to issuer Stock Option (right to buy)derivative | -75,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Timothy j Schroeder director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | Marcia Allen director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | James Kelly Ganjei director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | David J Moss Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +400,000 | - | - | 400,000 | Nov 18, 2025 |
| Nov 18, 2025 | Mark William Lowdell Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +400,000 | - | - | 400,000 | Nov 18, 2025 |
| Nov 18, 2025 | Scott Juda director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | Cory Randall Ellspermann Interim CFO | AGrant or award Stock Option (right to buy)derivative | +75,000 | - | - | 75,000 | Nov 18, 2025 |
| Nov 18, 2025 | Cory Randall Ellspermann Interim CFO | DDisposition to issuer Stock Option (right to buy)derivative | -40,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Marcia Allen director | DDisposition to issuer Stock Option (right to buy)derivative | -15,975 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Mark William Lowdell Chief Scientific Officer | DDisposition to issuer Stock Option (right to buy)derivative | -180,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | David J Moss Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -59,337 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Timothy j Schroeder director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | James Kelly Ganjei director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Scott Juda director | DDisposition to issuer Stock Option (right to buy)derivative | -108,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Cory Randall Ellspermann Interim CFO | AGrant or award Stock Option (right to buy)derivative | +40,000 | - | - | 40,000 | Nov 18, 2025 |
| Nov 18, 2025 | Scott Juda director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | Marcia Allen director | AGrant or award Stock Option (right to buy)derivative | +15,975 | - | - | 15,975 | Nov 18, 2025 |
| Nov 18, 2025 | James Kelly Ganjei director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | Mark William Lowdell Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +180,000 | - | - | 180,000 | Nov 18, 2025 |
| Nov 18, 2025 | Timothy j Schroeder director | AGrant or award Stock Option (right to buy)derivative | +108,000 | - | - | 108,000 | Nov 18, 2025 |
| Nov 18, 2025 | David J Moss Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +59,337 | - | - | 59,337 | Nov 18, 2025 |
| Nov 18, 2025 | Cory Randall Ellspermann Interim CFO | DDisposition to issuer Stock Option (right to buy)derivative | -30,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Marcia Allen director | DDisposition to issuer Stock Option (right to buy)derivative | -19,025 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | James Kelly Ganjei director | DDisposition to issuer Stock Option (right to buy)derivative | -15,975 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Timothy j Schroeder director | DDisposition to issuer Stock Option (right to buy)derivative | -15,975 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | David J Moss Chief Executive Officer | DDisposition to issuer Stock Option (right to buy)derivative | -275,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Mark William Lowdell Chief Scientific Officer | DDisposition to issuer Stock Option (right to buy)derivative | -104,000 | - | - | 0 | Nov 18, 2025 |
| Nov 18, 2025 | Scott Juda director | DDisposition to issuer Stock Option (right to buy)derivative | -15,975 | - | - | 0 | Nov 18, 2025 |
50 of 120 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Marcia Allendirector
- Ronnie Duane Clarkdirector
- Cory Randall EllspermannCFO
- James Kelly Ganjeidirector
- Scott Judadirector
- Mark William LowdellChief Scientific Officer
- David J MossChief Executive Officer
- James Sapirsteindirector, ceo, officer
- Timothy j Schroederdirector
Questions about INMB
Answered from the filings on this page, as of the latest one.
Are insiders buying INMB?
No. In the last 90 days no insider at Inmune Bio, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade INMB on the open market?
No open-market trade has been scored at Inmune Bio, Inc.. The latest Form 4 on file was filed on Sep 23, 2026 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Inmune Bio, Inc.?
9 people have filed a Form 4 at Inmune Bio, Inc., among them Marcia Allen (director), Ronnie Duane Clark (director), Cory Randall Ellspermann (CFO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.